The Securities and Exchange Commission has approved DOD Biotech Public Company Limited's request to extend the deadline for submitting its revised first quarter 2026 financial statements to 14 August 2026, from the original deadline of 27 July 2026. The company sought the extension due to a large volume of supporting documents and transaction details, requiring the auditor additional time for thorough review to ensure the financial statements are fully accurate and complete. Previously, the SEC issued a letter dated 25 June 2026 instructing the company to amend the financial statements regarding prepayments and advance payments, and the company submitted some related documents on 10 July 2026, before receiving the extension approval letter number 154/2026 dated 17 July 2026.
DOD Biotech Public Company LimitedSEC extension for financial restatement due to auditor review, but no indication of outcome or material impact.